Autoimmune hepatitis

Autoimmunity Reviews

Volumn 2, Issue 5, 2003, Pages 241-247

  Vergani, Diego ^a   Mieli Vergani, Giorgina ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune hepatitis; Molecular mimicry

Indexed keywords

AUTOANTIBODY;

AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENICITY; REVIEW;

EID: 0043264326     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00017-X     Document Type: Review

References (37)

1. Donaldson P.T., Doherty D.G., Hayllar K.M., McFarlane I.G., Johnson P.J., Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 13:(4):1991;701-706.
2. Gregorio G.V., Portmann B., Reid F., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 25:(3):1997;541-547.
3. Maggiore G., Veber F., Bernard O., et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr. 17:(4):1993;376-381.
4. Johnson P.J., McFarlane I.G., Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 333:(15):1995;958-963. see comments.
5. Alvarez F., Ciocca M., Canero-Velasco C., et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 30:(2):1999;222-227.
6. Richardson P.D., James P.D., Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 33:(3):2000;371-375.
7. Senaldi G., Portmann B., Mowat A.P., Mieli-Vergani G., Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child. 67:(12):1992;1447-1453.
8. Nouri-Aria K.T., Donaldson P.T., Hegarty J.E., Eddleston A.L., Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol. 1:(3):1985;235-241.
9. Nouri-Aria K.T., Lobo-Yeo A., Vergani D., Mieli-Vergani G., Eddleston A.L., Mowat A.P. T suppressor cell function and number in children with liver disease. Clin Exp Immunol. 61:(2):1985;283-289.
10. Nouri-Aria K.T., Hegarty J.E., Alexander G.J., Eddleston A.L., Williams R. Effect of corticosteroids on suppressor-cell activity in 'autoimmune' and viral chronic active hepatitis. N Engl J Med. 307:(21):1982;1301-1304.
11. Vento S., Hegarty J.E., Bottazzo G., Macchia E., Williams R., Eddleston A.L. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet. 1:(8388):1984;1200-1204.
12. Lobo-Yeo A., Senaldi G., Portmann B., Mowat A.P., Mieli-Vergani G., Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology. 12:(2):1990;224-232.
13. Chen M., Shirai M., Liu Z., Arichi T., Takahashi H., Nishioka M. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells. J Virol. 72:(10):1998;8301-8308.
14. Lobo-Yeo A., Alviggi L., Mieli-Vergani G., Portmann B., Mowat A.P., Vergani D. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol. 67:(1):1987;95-104.
15. Czaja A.J., Donaldson P.T. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 174:2000;250-259.
16. Wen L., Peakman M., Mowat A.P., et al. Gamma/delta+T cell clones from liver biopsies of children with autoimmune chronic active hepatitis (aCAH) and primary sclerosing cholangitis (aPSC) are cytotoxic to human liver target cells. J Hepatol. 13:1991;S80.
17. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA. 97:(10):2000;5498-5503.
18. Jensen D.M.M.I., Portmann B., et al. Detection of antibodies directed against a liver-specific lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med. 299:1978;1-7.
19. McFarlane B.M., McSorley C.G., Vergani D., McFarlane I.G., Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 3:(2):1986;196-205.
20. Ma Y., Gaken J., McFarlane B.M., et al. Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Gastroenterology. 112:(2):1997;483-492.
21. Vergani D., Mieli-Vergani G., Mondelli M., Portmann B., Eddleston A.L. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver. 7:(6):1987;307-315.
22. Mieli-Vergani G., Vergani D., Jenkins P.J., et al. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol. 38:(1):1979;16-21.
23. Wen L., Peakman M., Lobo-Yeo A., et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet. 336:(8730):1990; 1527-1530.
24. Lohr H., Manns M., Kyriatsoulis A., et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 84:(2):1991;297-302.
25. Lohr H., Treichel U., Poralla T., Manns M., Meyer zum Buschenfelde K.H. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol. 88:(1):1992;45-49.
26. Homberg J.C., Abuaf N., Bernard O., et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of 'autoimmune' hepatitis. Hepatology. 7:(6):1987;1333-1339.
27. Gueguen M., Meunier-Rotival M., Bernard O., Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med. 168:(2):1988;801-806.
28. Muratori L., Parola M., Ripalti A., et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut. 46:(4):2000;553-561.
29. Vergani D. LKM antibody: getting in some target practice. Gut. 46:(4):2000;449-450.
30. Leri O., Paparo Barbaro S., Sinopoli M.T., Marcelli V., De Rosa F.G., De Luca D. Type 2 autoimmune hepatitis and hepatitis C viraemia. Riv Eur Sci Med Farmacol. 18:(1):1996;3-6.
31. Muratori L., Lenzi M., Cataleta M., et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol. 21:(2):1994;199-203.
32. Vergani D., Mieli-Vergani G. Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6. Clin Exp Immunol. 92:(3):1993;367-368. editorial comment.
33. Yamamoto A.M., Cresteil D., Boniface O., Clerc F.F., Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol. 23:(5):1993;1105-1111.
34. Bogdanos D.P., Choudhuri K., Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 21:(4):2001;225-232.
35. Kerkar N., Choudhuri K., Ma Y., et al. CYP2D6193-212: a new immunodominant epitope and target of virus/self cross-reactivity in LKM1 positive liver disease. J Immunol. 170:2003;1481-1489.
36. Manns M.P., Griffin K.J., Sullivan K.F., Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 88:(4):1991;1370-1378.
37. Aichele P., Bachmann M.F., Hengartner H., Zinkernagel R.M. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev. 152:1996;21-45.